IL6 and type 1 diabetes mellitus: Currently, the clinical trial EXTEND (Clinical trial NCT02293837; www.clinicaltrials.gov) is examining whether the blockade of IL-6 signaling (tocilizumab, an anti-IL-6 receptor antibody)) can induce a protection of beta cell function in T1D patients (ages 6 to 17 years) is ongoing.